Ex­clu­sive: Con­nect Bio­phar­ma re­ports a PhII fail for Zeposia chal­lenger, and ex­ecs ap­pear ready to punt

Con­nect Bio­phar­ma is at­tempt­ing to play catch-up to big­ger names in the S1P mod­u­la­tor race, such as Bris­tol My­ers Squibb and Pfiz­er, now that the lat­ter has scooped up Are­na. But Con­nect’s Phase II study eval­u­at­ing the pro­gram in ul­cer­a­tive col­i­tis did not achieve its pri­ma­ry goal, leav­ing the biotech search­ing for a part­ner to take on de­vel­op­ment costs.

In the mid-stage study test­ing two dos­es, Con­nect’s tri­al for CBP-307 showed the high­er dose did not sig­nif­i­cant­ly re­duce stool fre­quen­cy, rec­tal bleed­ing and en­doscopy scores from base­line lev­els when com­pared to place­bo. Re­searchers mea­sured the rate of events af­ter 12 weeks us­ing a com­pos­ite analy­sis known as the Adapt­ed Mayo Score.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER